EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Awarded Notice of Allowance For key Patent Combining Use Of The Co's Proprietary Genetic Diagnostic With AD04 To Treat Alcohol And Drug Dependence
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals has been awarded a Notice of Allowance for a key patent that combines the use of the company's proprietary genetic diagnostic with AD04 to treat alcohol and drug dependence.
October 19, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adial Pharmaceuticals' new patent could potentially increase the company's market share in the alcohol and drug dependence treatment market.
The award of a new patent to Adial Pharmaceuticals for a unique treatment method could potentially increase the company's competitiveness and market share in the alcohol and drug dependence treatment market. This could lead to increased revenues and profitability, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100